87. Nat Rev Clin Oncol. 2018 Jun 21. doi: 10.1038/s41571-018-0059-2. [Epub ahead ofprint]Ribociclib effective in HR+, HER2- breast cancer.Sidaway P(1).Author information: (1)Nature Reviews Clinical Oncology, . nrclinonc@nature.com.DOI: 10.1038/s41571-018-0059-2 PMID: 29930396 